Literature DB >> 24457377

Src inhibition is still a relevant target in pancreatic cancer.

Thomas J George1, Jose G Trevino, Chen Liu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24457377      PMCID： PMC3926798          DOI： 10.1634/theoncologist.2013-0410

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  12 in total

1.  Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.

Authors:  Nagathihalli S Nagaraj; J Joshua Smith; Frank Revetta; M Kay Washington; Nipun B Merchant
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

2.  Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.

Authors:  Jose G Trevino; Justin M Summy; Donald P Lesslie; Nila U Parikh; David S Hong; Francis Y Lee; Nicholas J Donato; James L Abbruzzese; Cheryl H Baker; Gary E Gallick
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

3.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

4.  Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.

Authors:  Maksim V Yezhelyev; Gudrun Koehl; Markus Guba; Thomas Brabletz; Karl-Walter Jauch; Anderson Ryan; Alan Barge; Tim Green; Michael Fennell; Christiane J Bruns
Journal:  Clin Cancer Res       Date:  2004-12-01       Impact factor: 12.531

5.  Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis.

Authors:  Gareth J Griffiths; Mei Yee Koh; Valerie G Brunton; Christopher Cawthorne; Natalie A Reeves; Martin Greaves; Michael J Tilby; D Graham Pearson; Christopher J Ottley; Paul Workman; Margaret C Frame; Caroline Dive
Journal:  J Biol Chem       Date:  2004-08-23       Impact factor: 5.157

6.  Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.

Authors:  Mark S Duxbury; Hiromichi Ito; Michael J Zinner; Stanley W Ashley; Edward E Whang
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

7.  Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.

Authors:  Scott Kopetz; Donald P Lesslie; Nikolas A Dallas; Serk I Park; Marjorie Johnson; Nila U Parikh; Michael P Kim; James L Abbruzzese; Lee M Ellis; Joya Chandra; Gary E Gallick
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

8.  Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness.

Authors:  Hiromichi Ito; James Gardner-Thorpe; Michael J Zinner; Stanley W Ashley; Edward E Whang
Journal:  Surgery       Date:  2003-08       Impact factor: 3.982

9.  Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.

Authors:  I Ischenko; P Camaj; H Seeliger; A Kleespies; M Guba; E N De Toni; B Schwarz; C Graeb; M E Eichhorn; K-W Jauch; C J Bruns
Journal:  Oncogene       Date:  2008-09-15       Impact factor: 9.867

10.  Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma.

Authors:  José G Treviño; Smitha Pillai; Sateesh Kunigal; Sandeep Singh; William J Fulp; Barbara A Centeno; Srikumar P Chellappan
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715
View more
  6 in total

1.  Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation.

Authors:  Yi-Pei Lin; Jun-I Wu; Chien-Wei Tseng; Huei-Jane Chen; Lu-Hai Wang
Journal:  Oncogene       Date:  2018-09-03       Impact factor: 9.867

2.  Elucidation of the roles of the Src kinases in pancreatic acinar cell signaling.

Authors:  Bernardo Nuche-Berenguer; Paola Moreno; R T Jensen
Journal:  J Cell Biochem       Date:  2015-01       Impact factor: 4.429

3.  A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer.

Authors:  David Paladino; Peibin Yue; Hideki Furuya; Jared Acoba; Charles J Rosser; James Turkson
Journal:  Oncotarget       Date:  2016-02-09

4.  CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.

Authors:  Elisa M Noll; Christian Eisen; Albrecht Stenzinger; Elisa Espinet; Alexander Muckenhuber; Corinna Klein; Vanessa Vogel; Bernd Klaus; Wiebke Nadler; Christoph Rösli; Christian Lutz; Michael Kulke; Jan Engelhardt; Franziska M Zickgraf; Octavio Espinosa; Matthias Schlesner; Xiaoqi Jiang; Annette Kopp-Schneider; Peter Neuhaus; Marcus Bahra; Bruno V Sinn; Roland Eils; Nathalia A Giese; Thilo Hackert; Oliver Strobel; Jens Werner; Markus W Büchler; Wilko Weichert; Andreas Trumpp; Martin R Sprick
Journal:  Nat Med       Date:  2016-02-08       Impact factor: 53.440

Review 5.  Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy.

Authors:  Ashleigh Parkin; Jennifer Man; Paul Timpson; Marina Pajic
Journal:  FEBS J       Date:  2019-08-05       Impact factor: 5.542

Review 6.  Nuclear Functions of the Tyrosine Kinase Src.

Authors:  Giulia Bagnato; Martina Leopizzi; Enrica Urciuoli; Barbara Peruzzi
Journal:  Int J Mol Sci       Date:  2020-04-11       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.